• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pharma industry news

reslizumab

Teva files MAA for asthma treatment reslizumab

28 July 2015

Teva has successfully filed a MAA with the EMA for reslizumab -a humanised anti-IL-5 monoclonal antibody for the treatment of inadequately controlled asthma...

Atezolizumab

Atezolizumab could spur bladder cancer treatment innovation

28 July 2015

Atezolizumab is poised to become a major bladder cancer therapy in the race for FDA approval, following its promising performance in recent Phase II trials...

meningitis-c

Africa risks large meningitis C outbreak

28 July 2015

Four public health organisations have warned of acute shortages of meningitis C-containing vaccine as the risk of a meningitis C outbreak in Africa grows...

hepatitis-c

PHE publishes annual report on hepatitis C

28 July 2015

The latest figures from Public Health England show hospital admissions from hepatitis C-related end-stage liver disease and liver cancer continue to rise...

dengue

Sanofi Pasteur’s dengue vaccine candidate safely protects pre-adolescents

28 July 2015

New data analyses provide a comprehensive picture of the potential public health impact of vaccinating pre-adolescents and adults against dengue...

HM61713

Boehringer Ingelheim obtains exclusive rights to HM61713

28 July 2015

Boehringer Ingelheim has entered an exclusive and collaboration agreement for the development and global commercialisation rights of HM61713...

teva

Teva withdraws proposal to acquire Mylan

28 July 2015

Following yesterday’s news that Teva is to acquire Allergan’s global generics business, Teva has withdrawn its cash and stock proposal to acquire Mylan...

fungal

Fungal resistance represents a huge healthcare threat, warns ESCMID

28 July 2015

ESCMID is imploring global healthcare professionals and bodies to take a more active role in the growing problem of fungal resistance...

obizur

CHMP adopts positive opinion of Obizur for haemophilia A

28 July 2015

The CHMP has adopted a positive opinion for the marketing authorisation of Obizur for the treatment of bleeding episodes in patients with haemophilia...

allergan-dry-eye

Allergan to acquire Naurex; divests generics business to Teva

27 July 2015

Allergan followed an announcement it made yesterday about its acquisition of Naurex with news today that it is to divest its generics business to Teva...

empliciti

EMA grants accelerated assessment of MAA for Empliciti

27 July 2015

The EMA validated for review the Marketing Authorisation Application (MAA) for Empliciti for the treatment of multiple myeloma...

Technivie

FDA approves Technivie for GT4 chronic HCV

27 July 2015

The US FDA has approved AbbVie’s Technivie in combination with ribavirin for the treatment of adults with genotype 4 chronic hepatitis C virus infection...

 

Webinar: Increasing throughput and sensitivity of LC-MS assaysWATCH NOW
+